Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Plant-strengthening agent enhances natural ability of plants to survive
2015-07-27

Drought, diseases, and fungi. These are factors that farmers have no control over, and they often have to watch despondently as their crops are damaged. In addition, the practice of breeding plants in special and strictly-controlled conditions, has resulted in crops losing the chemical ability to protect themselves in nature.

Researchers in the Department of Soil, Crop, and Climate Sciences at the University of the Free State (UFS) have developed an organic agent that restores this chemical imbalance in plants. It enables the plant to build its own resistance against mild stress factors, and thus ensures increased growth and yield by the plant.

ComCat®, a plant-strengthening agent, is the result of extensive research by the German company, Agraforum AG, together with the UFS. Commercialisation was initially limited to Europe, while research was done at the UFS.

“Plants have become weak because they were grown specially and in isolation. They can’t protect themselves any longer,” says Dr Elmarie van der Watt from the department.

Dr Van der Watt says that, in nature, plants communicate by means of natural chemicals as part of their resistance mechanisms towards various stress conditions. These chemicals enable them to protect themselves against stress conditions, such as diseases and fungi (biotic conditions) or wind and droughts (abiotic conditions).

Most wild plant varieties are usually well-adapted to resist these stress factors. However, monoculture crops have lost this ability to a large extent.

The European researchers extracted these self-protection chemicals from wild plants, and made them available to the UFS for research and development.

“This important survival mechanism became dormant in monoculture crops. ComCat® wakes the plant up and says ‘Hey, you should start protecting yourself’.”

Research over the last few years has shown that the agent, applied mostly as a foliar spray, subsequently leads to better seedlings, as well as to growth, and yields enhancement of various crops. This is good news for the agricultural sector as it does not induce unwanted early vegetative growth that could jeopardise the final yield ? as happened in the past for nitrogen application at an early growth stage.

“The use of synthetic agents, such as fungicides which contain copper, are now banned. Nowadays, options for natural and organic agriculture is being investigated. This product is already widely used in Europe, but because farmers are often swamped by quacks, the South African market is still somewhat sceptical.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept